Research across Cancer
Related studies from across the Cancer family.
Multiparametric MRI and image-guided neurointerventions provide critical roles in brain tumor management and surveillance
Advanced Imaging and Interventions Improve Brain Tumor Management
This narrative review examines the roles of advanced diagnostic imaging and image-generated neurointerventions in managing brain tumors, inc…
Newer imaging techniques and minimally invasive procedures are expanding how doctors detect, plan, and treat various types of brain tumors.
EBV prevalence varies widely across lymphoma subtypes, highest in ENKTL at 92.4%
EBV Presence Linked to Lymphoma Cases in People with HIV
This meta-analysis of 307 studies and over 21,140 lymphoma cases quantifies Epstein-Barr virus (EBV) prevalence across lymphoma subtypes, st…
A large review of over 21,000 cases shows that the Epstein-Barr virus is more common in certain lymphoma types among people living with HIV.
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature
AI for leukemia diagnosis still fragmented, review finds
This scoping review evaluates deep learning techniques for leukemia detection across morphological, immunophenotyping, and molecular modalit…
A new review shows AI tools for leukemia diagnosis are promising but fragmented, with few using multiple data types.
CircRNAs act as signaling hubs for immune checkpoints and indicators of ICI response in lymphoma
CircRNAs May Help Predict Response to Lymphoma Immunotherapy
This systematic review examines the role of circRNAs, including EBV-encoded types, in immune evasion within lymphomas. The authors conclude …
New research suggests that specific molecules called circRNAs could help doctors predict how patients with lymphoma will respond to immune c…
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
New lung cancer treatments show better results but higher costs
This network meta-analysis evaluated the cost-effectiveness of three immunotherapy-based combinations compared to chemotherapy in patients w…
Newer drug combinations offer better survival for certain lung cancer patients, but high costs currently make them difficult to fund widely.
Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL
Trial shows promising results for relapsed large B-cell lymphoma
This Phase III randomized controlled trial analyzed a subgroup of 16 Japanese patients with relapsed or refractory large B-cell lymphoma. Th…
A new treatment combination showed a high response rate and longer progression-free survival for patients with a specific type of lymphoma.
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma
Comparison of two CAR-T cell therapies for lymphoma
This meta-analysis compared axicabtagene ciloleucel and tisagenlecleucel for the treatment of large B-cell lymphoma. While axicabtagene cilo…
New data comparing axicabtagene ciloleucel and tisagenlecleucel shows different levels of early response and safety risks for lymphoma patie…
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC
Trial shows serplulimab improves survival in certain lung cancers
This Phase III randomized controlled trial of 636 treatment-naïve patients with locally advanced or metastatic nsq-NSCLC found that serpluli…
A new clinical trial shows that adding serplulimab to chemotherapy can extend life for patients with specific types of non-small cell lung c…
Anti-CD19 shRNA-engineered CAR-T cells achieve an 88% overall response rate in B-cell acute lymphoblastic leukemia
CAR-T Cells Show Promise for B-cell Acute Lymphoblastic Leukemia
This meta-analysis evaluates anti-CD19 shRNA-engineered CAR-T cells (interleukin-6 knockdown) for patients with B-cell acute lymphoblastic l…
New research into modified CAR-T cells shows high response rates in patients with a specific type of leukemia while managing serious side ef…
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.